Literature DB >> 10349911

Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization.

Y Gazitt1, C O Freytes, N Callander, T W Tsai, M Alsina, J Anderson, L Holle, J Cruz, P Devore, M McGrath, G West, R Alvarez, W Montgomery.   

Abstract

PBSC are the preferred source of stem cells for autologous transplantation. However, regardless of the mobilization procedure used, 10%-20% of patients fail to collect an adequate number to ensure prompt engraftment. There is as yet no standard mobilization procedure for patients who fail a first mobilization attempt. Here, we describe a highly efficient strategy to obtain an adequate number of stem cells for patients who failed a first mobilization attempt. Seventy-four patients with various hematologic malignancies underwent initial mobilization with various regimens including hematopoietic growth factors with or without chemotherapy. In 72% of patients, > or =2 x 10(6) CD34+ stem cells/kg were collected in the initial mobilization attempt, and patients engrafted in a median of 10 days for neutrophils and 12 days for platelets. Eighteen patients failed to mobilize adequate numbers of stem cells, defined as the inability to collect 0.2 x 10(6) CD34+ stem cells/kg/day in the first 2-3 days. These patients had their apheresis halted. Patients were immediately given G-CSF (32 microg/kg/day) for 4 days as a second attempt at mobilization. Eighty-eight percent of these patients achieved the target of > or =2 x 10(6) CD34+ cells/kg, with a median duration of apheresis of 5 days (including the first and second mobilizations). The mean CD34+ cells/kg/day increased after administration of high-dose G-CSF from 0.16 after the first mobilization attempt to 0.61 (p = 0.0002) after the second mobilization. All patients engrafted in a median of 11 and 13 days for neutrophils and platelets, respectively. We conclude that patients whose apheresis yield is <0.4 x 10(6) CD34+ cells/kg after the first two apheresis collections can be successfully mobilized if high-dose G-CSF is administered immediately and continued until achieving > or =2 x 10(6) CD34+ stem cells/kg.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349911     DOI: 10.1089/106161299320442

Source DB:  PubMed          Journal:  J Hematother        ISSN: 1061-6128


  7 in total

1.  A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.

Authors:  Heather Renfroe; Mike Arnold; Louette Vaughn; R Donald Harvey; Ellie Hamilton; Sagar Lonial; H Jean Khoury; Jonathan L Kaufman; Mary Jo Lechowicz; Christopher R Flowers; Edmund K Waller
Journal:  Transfusion       Date:  2011-02-18       Impact factor: 3.157

2.  Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Authors:  Nigel Russell; Kenny Douglas; Anthony D Ho; Mohamad Mohty; Kristina Carlson; G J Ossenkoppele; Giuseppe Milone; Macarena Ortiz Pareja; Daniel Shaheen; Arnold Willemsen; Nicky Whitaker; Christian Chabannon
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

Review 3.  Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia.

Authors:  Lars U W Müller; David A Williams
Journal:  Mutat Res       Date:  2009-04-02       Impact factor: 2.433

4.  Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation.

Authors:  Mark A Fiala; Soo Park; Michael Slade; John F DiPersio; Keith E Stockerl-Goldstein
Journal:  Transfusion       Date:  2016-06-17       Impact factor: 3.157

5.  Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.

Authors:  A Olivieri; M Marchetti; R Lemoli; C Tarella; A Iacone; F Lanza; A Rambaldi; A Bosi
Journal:  Bone Marrow Transplant       Date:  2011-05-30       Impact factor: 5.483

Review 6.  Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization.

Authors:  Jian Chen; Hillard M Lazarus; Parastoo B Dahi; Scott Avecilla; Sergio A Giralt
Journal:  Blood Rev       Date:  2020-10-31       Impact factor: 10.626

7.  Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Authors:  D J Green; W I Bensinger; L A Holmberg; T Gooley; B G Till; L E Budde; J M Pagel; S L Frayo; J E Roden; L Hedin; O W Press; A K Gopal
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.